Literature DB >> 18570009

Effects of anti-secretory factor (ASF) on irritable bowel syndrome (IBS). A double-blind, randomized study.

Rickard Ekesbo1, Peter M Nilsson, Kristina Sjölund.   

Abstract

OBJECTIVE: To evaluate the role of the endogenous protein anti-secretory factor (ASF) on the symptoms, especially loose stools, in irritable bowel ayndrome (IBS).
DESIGN: A diet with specially processed cereals (SPC) known to induce ASF production was used in patients with IBS, in an eight-week randomized, placebo-controlled study.
SUBJECTS: Eighty-two patients with IBS were randomized to a diet with either SPC or placebo. MAIN OUTCOME MEASURES: The overall clinical condition and the quality of life were measured by VAS and SF-36 questionnaire, respectively. The plasma levels of ASF were determined in 14 patients with dominating loose stools before and after diet.
RESULTS: All patients significantly (p<0.001) improved in IBS-related symptoms irrespective of active or placebo diet. In an active-diet sub-group with diarrhoea (n=11) there was a significant (p<0.05) correlation between the increase of plasma ASF level and the improvement on the VAS.
CONCLUSION: Both study groups improved significantly on the VAS but no additive effect was seen for the active treatment. In the sub-group with loose stools, the SPC diet induced ASF plasma levels in IBS patients and was correlated to significant symptom improvement in the individual patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570009      PMCID: PMC3406645          DOI: 10.1080/02813430802005894

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  28 in total

1.  The putative role of inflammation in the irritable bowel syndrome.

Authors:  S M Collins; T Piche; P Rampal
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

2.  The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases.

Authors:  N A CHAUDHARY; S C TRUELOVE
Journal:  Q J Med       Date:  1962-07

Review 3.  Treatment of irritable bowel syndrome: a review of randomised controlled trials.

Authors:  R Akehurst; E Kaltenthaler
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Food-related gastrointestinal symptoms in the irritable bowel syndrome.

Authors:  M Simrén; A Månsson; A M Langkilde; J Svedlund; H Abrahamsson; U Bengtsson; E S Björnsson
Journal:  Digestion       Date:  2001       Impact factor: 3.216

Review 5.  Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials.

Authors:  R C Spiller
Journal:  Am J Med       Date:  1999-11-08       Impact factor: 4.965

6.  Purification and characterization of a hormone-like factor which inhibits cholera secretion.

Authors:  I Lönnroth; S Lange
Journal:  FEBS Lett       Date:  1984-11-05       Impact factor: 4.124

7.  A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea.

Authors:  E Oddsson; J Rask-Madsen; E Krag
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

8.  Evolution of visceral sensitivity in patients with irritable bowel syndrome.

Authors:  Pierre Poitras; Monique Riberdy Poitras; Victor Plourde; Michel Boivin; Pierre Verrier
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

9.  An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome.

Authors:  M Simrén; H Abrahamsson; E S Björnsson
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

10.  Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome.

Authors:  V A Jones; P McLaughlan; M Shorthouse; E Workman; J O Hunter
Journal:  Lancet       Date:  1982-11-20       Impact factor: 79.321

View more
  1 in total

1.  Antisecretory Factor Modulates GABAA Receptor Activity in Neurons.

Authors:  V Bazzurro; E Gatta; Aroldo Cupello; S Lange; M Robello
Journal:  J Mol Neurosci       Date:  2018-01-07       Impact factor: 3.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.